臨床外科79巻9号

2024年09月発行

特集 徹底解説　大腸癌治療ガイドライン2024

詳説

術後補助化学療法（stage Ⅱ, Ⅲ）

著者： 加藤健志¹

所属機関： ¹国立病院機構大阪医療センターがんセンター・下部消化管外科

ページ範囲：P.980 - P.985

文献概要

【ポイント】
◆術後補助化学療法は，R0切除が行われた治癒切除例に対して再発を抑制し予後を改善する目的で行い，「再発予防」ではない．
◆再発リスクを有する（ハイリスク）stage Ⅱ，Ⅲに対し，術後合併症から回復し，主要臓器機能が保たれた症例では行うことが推奨される．
◆レジメンはオキサリプラチン（OX）併用，投与期間は6か月が推奨されるが，再発リスクが低い症例では3か月も選択肢となる．

参考文献

1）大腸癌研究会（編）：大腸癌治療ガイドライン—医師用2024年版．金原出版，2024

2）Reinert T, Henriksen TV, Christensen E, et al：Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to Ⅲ Colorectal Cancer. JAMA Oncol 5：1124-1131, 2019

3）Tie J, Cohen JD, Wang Y, et al：Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage Ⅲ Colon Cancer. JAMA Oncol 5：1710-1717, 2019

4）Wang Y, Li L, Cohen JD, et al：Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer. JAMA Oncol 5：1118-1123, 2019

5）Kotani D, Oki E, Nakamura Y, et al: Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med 29：127-134, 2023

6）Kannarkatt J, Joseph J, Kurniali PC, et al：Adjuvant Chemotherapy for Stage Ⅱ Colon Cancer：A Clinical Dilemma. J Oncol Pract 13：233-241, 2017

7）Baxter NN, Kennedy EB, Bergsland E, et al：Adjuvant Therapy for Stage Ⅱ Colon Cancer：ASCO Guideline Update. J Clin Oncol 40：892-910, 2022

8）Argilés G, Tabernero J, Labianca R, et al：Localised colon cancer：ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31：1291-1305, 2020

9）National Comprehensive Cancer Network（NCCN）：NCCN clinical practice guidelines in oncology.　https://www.nccn.org/professionals/physician_gls（最終アクセス：2021年5月6日）

10）Moertel CG, Fleming TR, Macdonald JS, et al：Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322：352-358, 1990

11）Wolmark N, Rockette H, Mamounas E, et al：Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon：results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 17：3553-3559, 1999

12）Shimada Y, Hamaguchi T, Mizusawa J, et al：Randomised phase Ⅲ trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage Ⅲ colorectal cancer who have undergone Japanese D2/D3 lymph node dissection：final results of JCOG0205. Eur J Cancer 50：2231-2240, 2014

13）Yoshida M, Ishiguro M, Ikejiri K, et al：S-1 as adjuvant chemotherapy for stage Ⅲ colon cancer：a randomized phase Ⅲ study（ACTS-CC trial）. Ann Oncol 25：1743-1749, 2014

14）Hamaguchi T, Shimada Y, Mizusawa J, et al：Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage Ⅲ colorectal cancer（JCOG0910）：an open-label, non-inferiority, randomised, phase 3, multicentre trial. Lancet Gastroenterol Hepatol 3：47-56, 2018

15）André T, Boni C, Mounedji-Boudiaf L, et al：Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350：2343-2351, 2004

16）Haller DG, Tabernero J, Maroun J, et al：Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage Ⅲ colon cancer. J Clin Oncol 29：1465-1471, 2011

17）Grothey A, Sobrero AF, Shields AF, et al：Duration of Adjuvant Chemotherapy for Stage Ⅲ Colon Cancer. N Engl J Med 378：1177-1188, 2018

18）Yoshino T, Oki E, Misumi T, et al：Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage Ⅲ Colon Cancer：The Randomized Phase Ⅲ ACHIEVE Trial. J Clin Oncol 40：3419-3429, 2022

19）André T, Meyerhardt J, Iveson T, et al：Effect of duration of adjuvant chemotherapy for patients with stage Ⅲ colon cancer（IDEA collaboration）：final results from a prospective, pooled analysis of six randomised, phase 3 trials. Lancet Oncol 21：1620-1629, 2020

20）Kotaka M, Yamanaka T, Yoshino T, et al：Safety data from the phase Ⅲ Japanese ACHIEVE trial：part of an international, prospective, planned pooled analysis of six phase Ⅲ trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage Ⅲ colon cancer. ESMO Open 3：e000354, 2018

21）Cohen R, Taieb J, Fiskum J, et al：Microsatellite Instability in Patients With Stage Ⅲ Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin：An ACCENT Pooled Analysis of 12 Adjuvant Trials. J Clin Oncol 39：642-651, 2021